Compare Entegris Inc (ENTG) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Neurocrine Biosciences Inc — how do they compare? Entegris Inc trades at $157 (market cap $22.95B), while Neurocrine Biosciences Inc trades at $151.32 (market cap $16.46B). The key difference: Entegris Inc is the larger of the two by market cap, and Entegris Inc pays a 0.27% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENTG | NBIX | |
|---|---|---|
Market Cap | $22.95B | $16.46B |
Sector | Technology | Health |
52-Week High | $184.00 | $185.50 |
52-Week Low | $68.80 | $123.10 |
Enterprise Value | $26.16B | $16.48B |
Dividend Yield | 0.27% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
